Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CREBBP | Q92793 | 2/20 | 0.34 |
| ▸ | EP300 | Q09472 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.32 |
| ▸ | CCR2 | P41597 | 1/20 | 0.31 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.30 |
| ▸ | SELE | P16581 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26912549 | 0.91 | KDM4C (0.35) | CREBBPEP300KMT2AGRIN1MEN1 | |
| SCHEMBL30684236 | 0.91 | KDM4C (0.35) | CREBBPEP300KMT2AGRIN1MEN1 | |
| SCHEMBL26913307 | 0.89 | CREBBP (0.36) | CREBBPEP300KMT2AGRIN1MEN1 | |
| SCHEMBL30684185 | 0.81 | CREBBP (0.34) | CREBBPEP300KMT2AGRIN1CCR2 | |
| SCHEMBL26913061 | 0.80 | KMT2A (0.37) | CREBBPEP300KMT2AGRIN1MEN1 | |
| SCHEMBL26912577 | 0.79 | KDM4C (0.33) | CREBBPEP300KMT2AGRIN1MEN1 | |
| SCHEMBL26912459 | 0.78 | KDM4C (0.34) | KMT2AGRIN1MEN1 | |
| SCHEMBL26913314 | 0.77 | SMN1; SMN2 (0.36) | KMT2APARP1MEN1 | |
| SCHEMBL26912575 | 0.77 | KDM4C (0.33) | CREBBPKMT2AMEN1 | |
| SCHEMBL26912274 | 0.76 | P2RX7 (0.33) | KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023235809-A1 | CGAS INHIBITORS | ELI LILLY AND COMPANY (US) | 2023-12-07 | — | — | WO | disclosed |
| US-20230391786-A1 | cGAS INHIBITORS | ELI LILLY AND COMPANY | 2023-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230391786-A1 | cGAS INHIBITORS | CGAS, STING1, TBK1 | CREBBP 168/4885EP300 1677/4885KMT2A 4427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.